Table of Contents Author Guidelines Submit a Manuscript
Advances in Pharmacological Sciences
Volume 2016, Article ID 8964849, 14 pages
http://dx.doi.org/10.1155/2016/8964849
Review Article

A Review on Potential Mechanisms of Terminalia chebula in Alzheimer’s Disease

1Pharmacological Research Center of Medicinal Plants, School of Medicine, Mashhad University of Medical Sciences, Mashhad 917794-8564, Iran
2Neurocognitive Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad 917794-8564, Iran

Received 25 November 2015; Revised 7 January 2016; Accepted 10 January 2016

Academic Editor: Berend Olivier

Copyright © 2016 Amir R. Afshari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The current management of Alzheimer’s disease (AD) focuses on acetylcholinesterase inhibitors (AChEIs) and NMDA receptor antagonists, although outcomes are not completely favorable. Hence, novel agents found in herbal plants are gaining attention as possible therapeutic alternatives. The Terminalia chebula (Family: Combretaceae) is a medicinal plant with a wide spectrum of medicinal properties and is reported to contain various biochemicals such as hydrolysable tannins, phenolic compounds, and flavonoids, so it may prove to be a good therapeutic alternative. In this research, we reviewed published scientific literature found in various databases: PubMed, Science Direct, Scopus, Web of Science, Scirus, and Google Scholar, with the keywords: T. chebula, AD, neuroprotection, medicinal plant, antioxidant, ellagitannin, gallotannin, gallic acid, chebulagic acid, and chebulinic acid. This review shows that T. chebula extracts and its constituents have AChEI and antioxidant and anti-inflammatory effects, all of which are currently relevant to the treatment of Alzheimer’s disease.

1. Introduction

Alzheimer’s disease (AD) is the leading cause of neurodegenerative disease in the geriatric population, accounting for approximately 5 million cases of dementia in the USA according to estimates from the Alzheimer’s Association in 2015. Since the disease incidence increases with the progression of age, the risk of developing AD doubles every 5 years, beginning at age 65. Given the growing elderly population in developed countries, projections of future AD prevalence show a fourfold increase through 2050. Consequently, AD has become a major economic health burden because of accrued high healthcare costs, morbidity, and mortality, not to mention the financial burden it has on family members and caregivers due to lost wages and productivity [1].

The pathogenesis of AD is very complicated, but typically cerebral atrophy is clearly evident in postmortem and imaging studies. Combined cortical, limbic, and subcortical pathology leads to dementia typical of AD. Classic microscopic features include neurofibrillary tangles and senile plaques. Also, the clinical features of AD are commonly characterized by psychopathological signs such as language deterioration, memory loss, visuospatial impairment, and poor judgment [2]. Additionally, in AD there is a gradual loss of various neurotransmitters particularly in the basal forebrain. Cholinergic transmission is the earliest and most conspicuously affected in AD. The nucleus basalis in the basal forebrain is affected comparatively early in the process and acetylcholine levels inside the spinal fluid and brain of AD patients quickly reduce with the progression of the disease. This fact supports the cholinergic hypothesis that acetylcholine diminution results in the cognitive decline observed in AD patients finally go to the first symptomatic treatment of AD [3].

Most of the drugs presently available to treat AD are acetylcholinesterase inhibitors (AChEIs): tacrine [4], rivastigmine [5], donepezil [6], and galantamine [7]; but unfortunately all of these drugs have limited effectiveness and side effects [4]. On the other hand, medicinal plants are starting to take an important role in disease treatment, in particular to treat psychiatric and neurological disorders. One reason is because of the discontentment with conventional treatments and another is because patients are seeking greater self-control over their healthcare decisions [8].

It seems that due to the indiscriminate and excessive use of drugs, their costs, side effects, and interactions, herbal medicines can be a suitable alternative to treat diseases because of their low costs, availability, and fewer drug interactions [9]. Therefore, the search for a new pharmacotherapy from medicinal plants to treat neurodegenerative disorders has remarkably advanced and there are several studies and documents that indicate a significant role of herbal medicines in the treatment of AD [1012]. One particular herbal remedy is Terminalia chebula Retz. (Combretaceae) because of its numerous and different types of phytoconstituents such as polyphenols, terpenes, anthocyanins, flavonoids, alkaloids, and glycosides. In traditional medicine, the fruits of the T. chebula, which hold various chemically active compounds responsible for its medicinal properties, have been used in Unani, Ayurveda, and homeopathic medicine since antiquity to treat geriatric diseases and improve memory and brain function [13, 14]. It is also commonly used to treat numerous diseases such as cancer, cardiovascular diseases, paralysis, leprosy, ulcers, gout, arthritis, epilepsy, cough, fever, diarrhea, gastroenteritis, skin disorders, urinary tract infection, and wound infections [15, 16]. Recent studies show that T. chebula is effective in the treatment of diabetes [17], bacterial and fungal infections [18, 19], immunodeficiency diseases [20, 21], hyperlipidemia [22], liver diseases [15, 23], stomach ulcer [24], and wounds [25]. Other pharmacological properties and beneficial effects of T. chebula are summarized in Table 1.

Table 1: Structure and pharmacological properties of T. chebula active ingredients.

Hence, this review article aims to sum up the published literature on the pharmacology and phytochemistry of T. chebula and its effects on the progression and treatment of AD in order to call attention to this plant as a novel alternative in the treatment of Alzheimer’s disease.

2. Terminalia chebula Retzius

Terminalia chebula Retzius (Family: Combretaceae), as a shade and ornamental tree with 250 species, is a medicinal plant that grows in the Middle East and tropical regions such as India, China, and Thailand. It can grow to be 25 meters tall and has a variable appearance and spreading branches. The color of the bark is dark brown and is usually cracked. Leaves are thin, elliptic-oblong, cordiform at the base, elliptical, and 7–12 cm long and 4–6.5 cm in width and have a leathery form with entire margins. The upper surface of the leaves is glabrous opposite of the surface beneath. The flowers are futile with a white to yellowish color and unsightly odor. Flowers have 5–7 cm long spikes, simple or branched, about 4 mm across. The ovary is inferior with 10 stamens. Fruits are yellow to orange-brown when ripe and 2.5–5 cm long and unruffled with an ovate-drupe shape [15, 61].

Moreover, it is called by various names by the local people. For example, in the Thai language the plant’s common name is “Kot Phung Pla,” and in Indian it is called “Kadukkaai”; and its other names are Black Myrobalan, Ink Tree, or Chebulic Myrobalan (Figure 1) [15].

Figure 1: T. chebula tree and fruits.
2.1. Scientific Classification

Its classification is Kingdom: Plantae, Division: Magnoliophyta, Class: Magnoliopsida, Order: Myrtales, Family: Combretaceae, Genus: Terminalia, and Species: Chebula [15].

2.2. Phytochemical Compositions of T. chebula
2.2.1. Hydrolysable Tannins

Tannins, as a part of the phenolic compounds, are oligomeric and have multiple structural units with free phenolic groups and their molecular weight ranges from 500 to 3000 D. The fruit pulp and dried pericarp of the seeds contain the highest amount of tannins [62]. Tannins consist of hydrolysable and nonhydrolysable tannins and hydrolysable tannins (i.e., gallotannins and ellagitannins) are the main compounds in T. chebula.

Gallotannins and ellagitannins are polymers found in the fruits of T. chebula [63]. Gallotannins contain gallic acid that has esterified and bonded with the hydroxyl group of a polyol carbohydrate such as glucose [64]. Ellagitannins are formed when oxidative linkage occurs in the galloyl groups in 1,2,3,4,6-pentagalloyl glucose. Ellagitannins differ from gallotannins in that their galloyl groups are linked through C–C bonds, whereas the galloyl groups in gallotannins are linked by depside bonds [65, 66].

Chebulagic acid, a benzopyran tannin, is widely distributed in several plant families: the Combretaceae [67], Euphorbiaceae, Leguminosae, Anacardiaceae, and Fabaceae [31]. Also, in the Combretaceae Family, chebulagic acid is the main constitute of the fruits T. bellerica, T. chebula, and Emblica officinalis [68].

Chebulinic acid, also known as 1,3,6-tri-O-galloyl-2,4-chebuloyl-β-D-glucopyranoside, is an ellagitannin found in the fruits of T. chebula or in the leaves of T. macroptera [31, 68].

2.2.2. Phenolic Compounds

Phenolic compounds include ellagic acid, a natural potent phenolic antioxidant found in the fruits of T. chebula [13]; gallic acid, a trihydroxybenzoic acid found as a part of hydrolysable tannins [69]; tannic acid, a polymer of gallic acid molecules and glucose [70]; and chebulic acid, another phenolic compound in the ripe fruits of T. chebula and a component of transformed ellagitannins such as chebulagic acid or chebulinic acid [41].

Glycosides are other phenolic compounds that are widely present in the Terminalia, rhubarb, Senna, and Aloe species. The pericarp of the T. chebula fruit contains anthraquinone glycosides [71]. Table 1 shows the main ingredients of T. chebula and their chemical structures.

2.2.3. Miscellaneous Compounds

In addition to the above, there are some other compounds that are also present and contribute towards the activity of the plant such as palmitic [72], stearic [73], oleic [74], linoleic [75], and arachidic acids [76], which are present in the fruit kernels.

2.2.4. Methods of Search

This research included articles from 1960 to 2015 that were found in various electronic databases: PubMed, Science Direct, Scopus, Web of Science, Scirus, and Google Scholar by using the search words: T. chebula, AD, neuroprotection, medicinal plant, antioxidant, ellagitannin, gallotannin, gallic acid, chebulagic acid, and chebulinic acid. Only current articles that reported the effects of T. chebula on AD were included in our study. Then, a comparison of the related mechanisms and evaluation of pharmacology effects in the treatment and progression of AD was done.

2.3. T. chebula and Alzheimer’s Disease
2.3.1. Acetyl Cholinesterase (AChE)

One of the hypotheses about AD is acetylcholine (ACh) deficiency in the synaptic cleft of the cerebral cortex that causes memory disturbance. Acetyl cholinesterase, also known as AChE or acetyl-hydrolase, is a hydrolase that hydrolyzes the neurotransmitter acetylcholine. AChE is found at mainly neuromuscular junctions and cholinergic brain synapses where its activity serves to terminate synaptic transmission. It is the primary target of inhibition by organophosphorus compounds such as nerve agents and pesticides. AChE has a very high catalytic activity; each molecule of AChE degrades about 25000 molecules of ACh per second, approaching the limit allowed by diffusion of the substrate [77]. During neurotransmission, ACh is released from the nerve into the synaptic cleft and binds to ACh receptors on the postsynaptic membrane, relaying the signal from the nerve. AChE, also located on the postsynaptic membrane, terminates the signal transmission by hydrolyzing Ach [78]. AChE is found in many types of conducting tissue: central and peripheral tissues, motor and sensory fibers, nerve and muscle, and cholinergic and noncholinergic fibers. The activity of AChE is higher in motor neurons than in sensory neurons [79]. AChE is also found on the red blood cell membranes [80]. Traditionally, necrosis is the pathway that had been thought to cause cell death in AD; however, now it is thought that ACh containing neurons are the most important pathway of neuronal death in AD. The cell death mechanisms in AD are deposition of Aβ, reduced energy metabolism and/or mitochondrial dysfunction, excitotoxicity, and oxidative stress and free radical production. These four mechanisms contribute to necrosis in various diseases such as stroke and AD. Inflammatory responses and their effects on trophic factor function have also been proposed as a main factor for cell death in AD. AChE induces an apoptotic and necrotic cell death by inducing membrane depolarization and NMDA receptor activation with consequent Ca2+ influx and modulation of the α7 nicotinic acetylcholine receptor in hippocampal cultures. Therefore, AChE has a main role in neurodegeneration and AChEIs could be effective in neuroprotection [8183]. Increasing expression of splice variants of AChE (R and S) as neuroprotective forms of AChE, with AChEIs, has been effective in preventing the progression of AD. In a study, expression of AChE-R and AChE-S decreased over a period of 12 months in untreated patients. In contrast, treatment with tacrine causes an upregulation in both variants (up to 117%) [84].

Inhibition of AChE leads to accumulation of ACh in the synaptic cleft and results in impeded neurotransmission [78]. The acetyl cholinesterase inhibitors (AChEIs) attenuate the cholinergic deficit underlying the cognitive and neuropsychiatric dysfunctions in patients with neurodegenerative disorders. So, inhibition of brain AChE has been the major therapeutic target of treatment strategies for AD, Parkinson’s disease, senile dementia, ataxia, and myasthenia gravis [85]. There are a few synthetic medicines with this mechanism, for example, tacrine, donepezil, and the natural product-based rivastigmine, to treat cognitive dysfunction and memory loss associated with AD [86]. However, these compounds have been reported to have their adverse effects including gastrointestinal disturbances and problems associated with bioavailability, which necessitates the interest in finding better AChE inhibitors from natural sources [87].

In this section we discuss the effectiveness of T. chebula and its constituents on brain functions.

2.3.2. Anticholinesterase Properties

Anticholinesterase properties of T. chebula have been reported in many studies [3, 8895]. In Sancheti et al.’s study, the inhibitory effects of T. chebula on AChE and butyrylcholinesterase (BChE) were reported. In the in vitro study, methanolic crude extract of the fruits of T. chebula with a concentration of 5 mg/mL inhibited AChE and BChE about 89% and 95%, respectively. Sancheti et al. extracted 1,2,3,4,6-penta-O-galloyl-β-D-glucose (PGG) with a gallotannin structure from T. chebula by chromatographic methods, and they showed it to be the most potent AChE and BChE inhibitor. Bioassay of PGG exhibited its concentration-dependent inhibitory activity on AChE and BChE with IC50 values of μM and μM, respectively. Then, for deducing the inhibitory activity of PGG, a TLC assay was done with tacrine as a positive control, and the AChE inhibitory effect was visualized clearly in the assay [88]. In addition to the inhibitory effect of methanolic fruit extracts of T. chebula on AChE, the ethyl acetate fraction shows relatively remarkable AChE inhibitory activity. Sulaiman et al. showed that ethyl acetate fraction with doses of 1, 5, 15, and 25 mg/mL inhibited AChE by 29.36%, 32.44%, 45.82%, and 62.32%, respectively. This fraction was more potent than the chloroform and methanolic fraction in AChE inhibition [91]. In a similar in vitro study, Vinutha et al. used the methanolic and aqueous extracts of the fruit of T. chebula and the data showed that IC50 values of the aqueous extract of T. chebula (minimum inhibition: 12.45%) are more potent than the methanolic extract (minimum inhibition: 1.21%) [3].

In addition to the effects of gallotannins on AChE inhibition, tannic acid as an active component of T. chebula has a potential inhibition effect on AChE. Upadhyay and Singh showed the competitive inhibition of AChE by tannic acid in vivo and in vitro. This study focused on the effects of tannic acid from the T. chebula fruit. In vivo treatment with 80% of LC50 of tannic acid during 96 h caused a remarkable inhibition in AChE activity in the nervous tissue of Lymnaea acuminate. Furthermore, maximum inhibition of AChE activity was detected when the tissue was exposed to 80% of LC50 of tannic acid for 96 h, so inhibition of AChE was time- and dose-dependent in the 96 h process. In vitro treatment showed that tannic acid caused dose-dependent AChE inhibition significantly, such that 0.04 mM of tannic acid reduced the AChE activity to 37% of the control in the nervous tissue of L. acuminata [92]. In addition, another in vivo research on AChE activity showed that tannic acid completely neutralized the AChE activity in Naja kaouthia venom [96].

Parle and Vasudevan in their in vivo study showed that Abana (a mixture of medicinal plants containing T. chebula) with doses of 50, 100, and 200 mg/kg administered orally for 15 days can reduce the brain AChE activity in young and aged mice. Passive avoidance apparatus and maze tests were performed on day 16 and the results showed a remarkable dose-dependent reduction in transfer latency and a significant increase in step-down latency tests, indicating significant improvement in memory [93].

Another similar study was done by Dhivya et al. In this in vitro study, AChE inhibitory activity of various plant species containing T. chebula was reported to have AChE inhibition of % (0.1 mg/mL) as well [95].

In a similar study, AChE inhibition of the methanolic extract of T. chebula showed a moderate inhibition with an extract with IC50 value of 180 14.6 μg/mL and the percentage of AChE inhibition was at 0.1 mg/mL [97]. In addition, the percentage of AChE inhibition in the extract of T. chebula was 13% (IC50 not detected) [14]. Furthermore, in another research, T. chebula could inhibit 89% of AChE activity (5 mg/mL) and 95% of BChE activity (5 mg/mL) [88].

Gallic acid and ellagic acid, as phenolic compounds in the fruits of T. chebula, could also inhibit AChE. Nag and De in their study showed that the inhibitory effect of the methanolic extract of T. chebula (gallic acid: 0.25 μg, ellagic acid: 0.08 μg) has a linear relationship with increasing dosage (IC50: 10.96) [89].

2.3.3. Anti-Inflammatory Properties

Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) are the key enzymes that are involved in inflammation. Reddy et al. investigated chebulagic acid, as a COX-LOX dual inhibitor, from the ethanolic extract of fruits of T. chebula. The results showed that chebulagic acid has a potent COX-LOX dual inhibition activity with IC50 values of , , and μM for COX-1, COX-2, and 5-LOX, respectively [76].

The water soluble fraction of T. chebula (WFTC) was effective against systemic and local anaphylaxis. Shin et al. showed that the injection of WFTC with doses of 0.01–1.0 g/kg inhibited anaphylactic shock 100%. When WFTC was pretreated at concentrations ranging from 0.005 to 1.0 g/kg, the serum histamine levels were reduced dose-dependently. In addition, this study showed that WFTC increased anti-dinitrophenol and IgE-induced tumor necrosis factor- (TNF-) α production [98].

Lee et al. in their study showed that gallic acid (25 μg) suppressed nuclear factor kappa B (NF-κB) activity and cytokine release. It also remarkably reduced the cyclic AMP response element binding protein/p300 (CBP/p300, a NF-κB coactivator) gene expression, acetylation levels, and CBP/p300 histone acetyltransferase activity. Therefore, gallic acid derived from the extracts of several plants especially T. chebula was shown to exert anti-inflammatory activity via the downregulation of the NF-κB pathway in the development of inflammatory diseases, both in vitro and in vivo [30, 99101].

Kim et al. showed that the inhibition of NF-κB acetylation with gallic acid resulted in reduced cytokine production in microglia cells and the protection of neuronal cells from amyloid β- (Aβ-) induced neurotoxicity. In addition, this research showed a restorative effect of gallic acid on Aβ-induced cognitive dysfunction in mice in Y-maze and passive avoidance tests. Therefore, gallic acid has several roles in neuroinflammatory diseases including (1) preventing Aβ-induced neuronal cell death by inhibiting RelA (as a gene encoding NF-κB) acetylation and cytokine production; (2) protecting neuronal cells from primary microglia-mediated Aβ neurotoxicity; (3) restoring Aβ-induced memory deficits in mice; and (4) suppressing in vivo cytokine production by inhibiting RelA acetylation in brain [101]. Another similar study showed that polyphenolic extracts (containing gallic acid) of medicinal plants such as T. chebula are able to inhibit Aβ aggregation, reduce Aβ production, and protect against Aβ neurotoxicity, in vitro [102]. Kim et al. reported the inhibitory effects of gallic acid on inflammatory responses via NF- κB and p38 mitogen-activated protein kinase pathways [103].

In another study, chebulagic acid showed a potent anti-inflammatory effect in lipopolysaccharide- (LPS) stimulated RAW 264.7 (mouse macrophage cell line). Reddy and Reddanna showed the effectiveness of chebulagic acid against inflammatory diseases by different mechanisms such as inhibition of nitric oxide (NO) and prostaglandin E2 production, downregulation of iNOS (inducible nitric oxide synthases), COX-2, 5-LOX, TNF-α, interleukin 6, and inhibitory effects on NF-κB, and decreases in nuclear p50 and p65 protein levels. In addition, the generation of reactive oxygen species (ROS) and phosphorylation of p38, ERK 1/2, and JNK in LPS-stimulated RAW 264.7 cells was suppressed by chebulagic acid in a concentration-dependent manner [44]. In another research, chebulagic acid from the immature seeds of T. chebula significantly suppressed the onset and progression of collagen induced arthritis in mice [104]. In a similar study, the aqueous extract of the dried fruit of T. chebula showed an anti-inflammatory effect by inhibiting iNOS [105]. Patil et al. in their study showed that administrating the fruit of T. chebula (500 mg/kg) via inhibition of iNOS expression can be significantly effective in the progression of inflammation [106]. In vivo anti-inflammatory activity of T. chebula fruit extract at different doses (range: 50 to 500 mg/kg) was evaluated against carrageenan-induced inflammation in rats. In this study, Bag et al. reported that 250 mg/kg (administrated orally) caused a 69.96% reduction in carrageenan-induced rat paw edema. This finding suggests that free radical quenching may be one of the mechanisms for its anti-inflammatory activity [107]. Triphala, an Indian Ayurvedic herbal formulation containing T. chebula, at a dosage of 1 g/kg, showed an anti-inflammatory effect. Sabina and Rasool in their research showed that the mechanisms of anti-inflammatory properties of this plant include (a) inhibition of lysosomal enzyme release, (b) a significant decrease of inflammatory mediator TNF-α, and (c) a decrease of beta-glucuronidase and lactate dehydrogenase enzymes release. The anti-inflammatory effect of Triphala might be due to the presence of phenolic components and flavonoids [108]. In another study, Ramani and Pradhan showed that the acetone extract of T. chebula fruits had a significant effect on controlling Complete Freund’s Adjuvant-induced arthritis. This effect leads to a good reduction in paw edema and joint thickness (reduction of ESR values and RF values) in comparison with dexamethasone [109].

2.3.4. Antioxidant Properties

Decreases in antioxidant defense or increases in oxidant status in the body tend to lead to the condition called oxidative stress, which plays a major role in neurological degeneration such as AD [110]. Reactive oxygen species and oxidative stress increase the formation of amyloid-β and senile plaques in the brain are the hallmark of AD [111]. High lipid content, deficient antioxidant values, and high oxygen consumption in the brain are the reasons the central nervous system is vulnerable to oxidative stress. Increased lipid peroxidation, decreased glutathione levels, increased dopamine turnover, and elevated iron and aluminum levels in the brain support the role of oxidative stress in Parkinson's, Amyotrophic Lateral Sclerosis, and AD [112].

In Table 2, we have summarized the roles of oxidative stress in the pathogenesis and progression of AD. Thus, reducing oxidative stress by enhancing antioxidant defense or decreasing the production of reactive oxygen species may be effective in treating AD.

Table 2: Major effects of oxidative stress in the pathogenesis of Alzheimer’s disease.

Antioxidant effects of T. chebula extract (100 μg/mL) were compared with reference radical scavengers such as quercetin, gallic acid, and t-butylhydroquinone, and T. chebula extract showed 95% activity with IC50 2.2 μg/mL [14]. Terminalia species such as T. chebula and T. arjuna with a high content of phenolic constituents showed strong antioxidant and antiaging properties [88]. Oral administration of aqueous extracts of T. arjuna causes significant elevation in the activities of antioxidant enzymes such as superoxide dismutase, catalase, and glutathione S-transferase. The strong antioxidant action of the aqueous extract of the Terminalia species may play a role in treating age-related diseases such as AD [127]. A similar study done by Mathew and Subramanian showed that the antioxidant activity of the methanolic extract of T. chebula (0.1 mg/mL) and IC50 was 86.3% and 0.5 μg/mL, respectively. In this study the highest amount of antioxidant activity among 20 plants was found in T. chebula due to the presence of gallic acid and ellagic acid. All 20 plants used in this study were traditional neuroprotective plants that have been used for many years and among them T. chebula was the most potent antioxidant and moderate inhibition of AchE [97]. In the evaluation of antioxidant, anti-inflammatory, membrane-stabilizing, and antilipid peroxidative effects of the hydroalcoholic extract of T. chebula fruits in arthritic disorders, Bag et al. showed that the fruit extract of T. chebula (10 to 100 μg/mL) in carrageenan-induced inflammation in rats reduced the formation of thiobarbituric acid reactive substances in the liver with IC50 94.96 mg/kg. The IC50 of the extract in DPPH radical-scavenging activity was 42.14 μg/mL [107]. Antilipid peroxidative capacity of T. chebula was attributed to higher phenolic content, reducing ability, Fe(II) chelating ability, and free radical-scavenging activity. In Khan et al.’s study, the aqueous extracts of yellow T. chebula and black T. chebula showed IC50 values of μg/mL and μg/mL in the scavenging of the DPPH radical in mice brains, respectively [128]. In an in vitro study done to investigate the biological activities of phenolic compounds and triterpenoid constituents of T. chebula, 9 phenolic compounds and 8 triterpenoids were extracted. Radical-scavenging activities of the phenolic compounds were higher than the triterpenoids compounds and had potent inhibitory activities against melanogenesis at a concentration of 10 μM and the IC50 was 1.4–10.9 μM. These results showed that T. chebula with a high content of polyphenolic ingredients was a potent antioxidant [16]. The extract of the dried fruit pulp of T. chebula (600 mg/kg) could diminish acetic acid-induced colitis in rats with antioxidant effects (free radical-scavenging, antioxidant enzymes enhancing activity and decreasing lipid peroxidation) [129].

In the evaluation of neuroprotective effects, the inhibition of H2O2-induced PC12 cell death by T. chebula was investigated. H2O2 at 40 μM for 12 h decreased cell viability to 59%. Also, all of the methanol, water, and 95% ethanol extracts of T. chebula increased cell viability at 0.5–5.0 μg/mL, dose-dependently; and among them the water extract was more potent. Antioxidant effects of the extracts were compared and the results showed that methanol extract had good antioxidant activity based on the luminol-H2O2-horseradish peroxidase assay and the water extract was shown to have good antioxidant activities in cupric sulfate phenanthroline-H2O2 and luminol-H2O2 assays. Also, 95% ethanol extract showed good antioxidant activity in the pyrogallol-luminol assay [130]. Effects of T. chebula seed extracts on brain-derived neurotrophic factor (BDNF), Cu, Zn-superoxide dismutase (SOD1), and Mn-superoxide dismutase (SOD2) were evaluated by Park et al. Extract with a dose of 100 mg/kg once a day was administrated to gerbils for 7 days before induction of transient cerebral ischemia and the neuroprotective effect of the extract was evaluated in the CA1 hippocampal region on the fourth day after ischemia-reperfusion induction. The results showed that astrocytes and microglia remarkably decreased in the ischemic group compared with the vehicle-treated group and neuron nucleus (as the positive neuron) was distinctively abundant (62%) compared to the vehicle-treated ischemia group (62% versus 12.2%). Protein levels and activity of SOD1, SOD2, and BDNF were much higher in the treated group. These results confirmed the neuroprotective effects of T. chebula extracts against neuronal damage in hippocampus [131]. Recently, we have found that the alcoholic extract of T. chebula fruits significantly protects against quinolinic acid-induced neurotoxicity by alleviating the oxidative stress parameters (unpublished data).

Many studies used T. chebula to modulate the oxidative stress adverse effects in various models of oxidation damage and aging [132134]. T. chebula could enhance the antioxidant defense and modulate oxidative stress due to aging in the liver and kidney of aged rats compared to young albino rats [133] and could protect hepatocytes from damage due to oxidative stress and enhanced total thiol content [41]. Many studies have shown the antioxidant activity of T. chebula in various in vivo and in vitro models [16, 135, 136]. In addition, most of the researchers agree with this hypothesis that “pharmacophore, which contains large numbers of –OH group (such as polyphenols), has greater anti-aging properties than those with less numbers of –OH groups.” Therefore, two constituents that are potent phenolic compounds are ellagic acid and 4-O-xyloside of ellagic acid. These active ingredients were investigated for their activities on free radical-scavenging, elastase inhibition, expression of matrix metalloproteinase-1 (MMP-1), and type I collagen synthesis in normal human fibroblast cells. Thus, ellagic acid may be useful for the geriatric population [137, 138].

According to the points mentioned above regarding the antioxidant activity of T. chebula and the important role of oxidative stress in the pathogenesis of AD, we can conclude that the use of this plant may be effective against the progression of AD.

3. Conclusion

Alzheimer’s disease is a debilitating dementia, and only a limited number of therapeutic options are currently available to modify the manifestations of the disease. T. chebula has pharmacological activities relevant to dementia therapy (Figure 2). Different extracts from T. chebula have exhibited concentration-dependent inhibitory activities on AChE and BChE. Such AChE activities are also described for its active ingredients such as PGG, gallic acid, ellagic acid, and tannic acid. Anti-inflammatory properties of T. chebula have been well documented in different experimental systems that could be attributed to chebulagic or gallic acid. T. chebula with a high content of phenolic constituents exhibits strong antioxidant and neuroprotective properties in vitro and in vivo. The efficacy of T. chebula in treating AD should be compared with the current standard pharmacological treatment in animal and clinical testing and researches. Such studies should include the identification of the active principle(s) in order to improve the validation of the clinical trials. Until then, this review provides some evidences on the benefits of T. chebula in the treatment of Alzheimer’s disease.

Figure 2: Anticholinesterase, anti-inflammatory, and antioxidant properties of T. chebula relevant to anti-Alzheimer’s therapy.

Conflict of Interests

The authors confirm that there is no conflict of interests.

References

  1. Y. Stern, “Cognitive reserve and Alzheimer disease,” Alzheimer Disease & Associated Disorders, vol. 20, no. 2, pp. 112–117, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. H.-R. Adhami, H. Farsam, and L. Krenn, “Screening of medicinal plants from Iranian traditional medicine for acetylcholinesterase inhibition,” Phytotherapy Research, vol. 25, no. 8, pp. 1148–1152, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Vinutha, D. Prashanth, K. Salma et al., “Screening of selected Indian medicinal plants for acetylcholinesterase inhibitory activity,” Journal of Ethnopharmacology, vol. 109, no. 2, pp. 359–363, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Chopra, S. Misra, and A. Kuhad, “Current perspectives on pharmacotherapy of Alzheimer's disease,” Expert Opinion on Pharmacotherapy, vol. 12, no. 3, pp. 335–350, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. S. López, J. Bastida, F. Viladomat, and C. Codina, “Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts,” Life Sciences, vol. 71, no. 21, pp. 2521–2529, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. G. L. Ellman, K. D. Courtney, V. Andres Jr., and R. M. Featherstone, “A new and rapid colorimetric determination of acetylcholinesterase activity,” Biochemical Pharmacology, vol. 7, no. 2, pp. 88–95, 1961. View at Publisher · View at Google Scholar · View at Scopus
  7. I. K. Rhee, M. van de Meent, K. Ingkaninan, and R. Verpoorte, “Screening for acetylcholinesterase inhibitors from Amaryllidaceae using silica gel thin-layer chromatography in combination with bioactivity staining,” Journal of Chromatography A, vol. 915, no. 1-2, pp. 217–223, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Anand and B. Singh, “A review on cholinesterase inhibitors for Alzheimer's disease,” Archives of Pharmacal Research, vol. 36, no. 4, pp. 375–399, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. M. M. Dirin, S. Mousavi, A. R. Afshari, K. Tabrizian, and M. H. Ashrafi, “Potential drug-drug interactions in prescriptions dispensed in community and hospital pharmacies in East of Iran,” Journal of Research in Pharmacy Practice, vol. 3, no. 3, pp. 104–107, 2014. View at Publisher · View at Google Scholar
  10. B. H. May, M. Lit, C. C. L. Xue et al., “Herbal medicine for dementia: a systematic review,” Phytotherapy Research, vol. 23, no. 4, pp. 447–459, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Akhondzadeh and S. H. Abbasi, “Herbal medicine in the treatment of Alzhelmer's disease,” American Journal of Alzheimer's Disease and other Dementias, vol. 21, no. 2, pp. 113–118, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. L. L. D. Santos-Neto, M. A. de Vilhena Toledo, P. Medeiros-Souza, and G. A. de Souza, “The use of herbal medicine in Alzheimer's disease—a systematic review,” Evidence-Based Complementary and Alternative Medicine, vol. 3, no. 4, pp. 441–445, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Saleem, M. Husheem, P. Härkönen, and K. Pihlaja, “Inhibition of cancer cell growth by crude extract and the phenolics of Terminalia chebula retz. fruit,” Journal of Ethnopharmacology, vol. 81, no. 3, pp. 327–336, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. S. K. Ali, A. R. Hamed, M. M. Soltan et al., “In-vitro evaluation of selected Egyptian traditional herbal medicines for treatment of Alzheimer disease,” BMC Complementary and Alternative Medicine, vol. 13, no. 1, p. 121, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Rathinamoorthy and G. Thilagavathi, “Terminalia chebula—review on pharmacological and biochemical studies,” International Journal of PharmTech Research, vol. 6, no. 1, pp. 97–116, 2014. View at Google Scholar · View at Scopus
  16. A. Manosroi, P. Jantrawut, E. Ogihara et al., “Biological activities of phenolic compounds and triterpenoids from the Galls of Terminalia chebula,” Chemistry & Biodiversity, vol. 10, no. 8, pp. 1448–1463, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. N. K. Rao and S. Nammi, “Antidiabetic and renoprotective effects of the chloroform extract of Terminalia chebula Retz. seeds in streptozotocin-induced diabetic rats,” BMC Complementary and Alternative Medicine, vol. 6, no. 1, article 17, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Aneja and R. Joshi, “Evaluation of antimicrobial properties of fruit extracts of Terminalia chebula against dental caries pathogens,” Jundishapur Journal of Microbiology, vol. 2, no. 3, pp. 105–111, 2009. View at Google Scholar
  19. B. Dutta, I. Rahman, and T. Das, “Antifungal activity of Indian plant extracts: antimyzetische Aktivität indischer Pflanzenextrakte,” Mycoses, vol. 41, no. 11-12, pp. 535–536, 1998. View at Publisher · View at Google Scholar
  20. V. Aher and A. Wahi, “Immunomodulatory activity of alcohol extract of Terminalia chebula retz combretaceae,” Tropical Journal of Pharmaceutical Research, vol. 10, no. 5, pp. 567–575, 2011. View at Google Scholar · View at Scopus
  21. M.-J. Ahn, C. Y. Kim, J. S. Lee et al., “Inhibition of HIV-1 integrase by galloyl glucoses from Terminalia chebula and flavonol glycoside gallates from Euphorbia pekinensis,” Planta Medica, vol. 68, no. 5, pp. 457–459, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. V. Maruthappan and K. S. Shree, “Hypolipidemic activity of Haritaki (Terminalia chebula) in atherogenic diet induced hyperlipidemic rats,” Journal of Advanced Pharmaceutical Technology and Research, vol. 1, no. 2, pp. 229–235, 2010. View at Google Scholar · View at Scopus
  23. S. Srigopalram and I. A. Jayraaj, “Effect of Terminalia chebula retz on den induced hepatocellular carcinogenesis in experimental rats,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 4, no. 2, pp. 440–445, 2012. View at Google Scholar · View at Scopus
  24. P. Sharma, T. Prakash, D. Kotresha et al., “Antiulcerogenic activity of Terminalia chebula fruit in experimentally induced ulcer in rats,” Pharmaceutical Biology, vol. 49, no. 3, pp. 262–268, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. M. P. Singh and C. S. Sharma, “Wound healing activity of Terminalia chebula in experimentally induced diabetic rats,” International Journal of PharmTech Research, vol. 1, no. 4, pp. 1267–1270, 2009. View at Google Scholar · View at Scopus
  26. C. Engels, M. Knödler, Y.-Y. Zhao, R. Carle, M. G. Gänzle, and A. Schieber, “Antimicrobial activity of gallotannins isolated from mango (Mangifera indica L.) kernels,” Journal of Agricultural and Food Chemistry, vol. 57, no. 17, pp. 7712–7718, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. X. Zhao, H. Sun, A. Hou, Q. Zhao, T. Wei, and W. Xin, “Antioxidant properties of two gallotannins isolated from the leaves of Pistacia weinmannifolia,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1725, no. 1, pp. 103–110, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Sangiovanni, U. Vrhovsek, G. Rossoni et al., “Ellagitannins from Rubus berries for the control of gastric inflammation: in vitro and in vivo studies,” PLoS ONE, vol. 8, no. 8, Article ID e71762, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. R. H. Hussein and F. K. Khalifa, “The protective role of ellagitannins flavonoids pretreatment against N-nitrosodiethylamine induced-hepatocellular carcinoma,” Saudi Journal of Biological Sciences, vol. 21, no. 6, pp. 589–596, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Lee, S. Y. Lee, Y. Son, and J. Yun, “Gallic acid decreases inflammatory cytokine secretion through histone acetyltransferase/histone deacetylase regulation in high glucose-induced human monocytes,” Journal of Medicinal Food, vol. 18, no. 7, pp. 793–801, 2015. View at Publisher · View at Google Scholar
  31. H. Walia and S. Arora, “Terminalia chebula—a pharmacognistic account,” Journal of Medicinal Plants Research, vol. 7, no. 20, pp. 1351–1361, 2013. View at Google Scholar
  32. D. H. Priscilla and P. S. M. Prince, “Cardioprotective effect of gallic acid on cardiac troponin-T, cardiac marker enzymes, lipid peroxidation products and antioxidants in experimentally induced myocardial infarction in Wistar rats,” Chemico-Biological Interactions, vol. 179, no. 2-3, pp. 118–124, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. L. D. Reynolds and N. G. Wilson, Scribes and Scholars, Cambridge University Press, Cambridge, UK, 1974.
  34. H.-H. Ho, C.-S. Chang, W.-C. Ho, S.-Y. Liao, C.-H. Wu, and C.-J. Wang, “Anti-metastasis effects of gallic acid on gastric cancer cells involves inhibition of NF-κB activity and downregulation of PI3K/AKT/small GTPase signals,” Food and Chemical Toxicology, vol. 48, no. 8-9, pp. 2508–2516, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. M. A. Farag, D. A. Al-Mahdy, R. Salah El Dine et al., “Structure—activity relationships of antimicrobial gallic acid derivatives from pomegranate and acacia fruit extracts against potato bacterial wilt pathogen,” Chemistry & Biodiversity, vol. 12, no. 6, pp. 955–962, 2015. View at Publisher · View at Google Scholar
  36. A. Ibrahim, R. El Kareem, and M. Sheir, “Elucidation of acrylamide genotoxicity and neurotoxicity and the protective role of gallic acid and green tea,” Journal of Forensic Toxicology & Pharmacology, vol. 4, no. 1, article 1, 2015. View at Publisher · View at Google Scholar
  37. S.-I. Hamada, T. Kataoka, J.-T. Woo et al., “Immunosuppressive effects of gallic acid and chebulagic acid on CTL-mediated cytotoxicity,” Biological and Pharmaceutical Bulletin, vol. 20, no. 9, pp. 1017–1019, 1997. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Sarkaki, H. Fathimoghaddam, S. M. T. Mansouri, M. S. Korrani, G. Saki, and Y. Farbood, “Gallic acid improves cognitive, hippocampal long-term potentiation deficits and brain damage induced by chronic cerebral hypoperfusion in rats,” Pakistan Journal of Biological Sciences, vol. 17, no. 8, pp. 978–990, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. O. S. Ajala, A. Jukov, and C.-M. Ma, “Hepatitis C virus inhibitory hydrolysable tannins from the fruits of Terminalia chebula,” Fitoterapia, vol. 99, pp. 117–123, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. A. T. Pham, K. E. Malterud, B. S. Paulsen, D. Diallo, and H. Wangensteen, “α-Glucosidase inhibition, 15-lipoxygenase inhibition, and brine shrimp toxicity of extracts and isolated compounds from Terminalia macroptera leaves,” Pharmaceutical Biology, vol. 52, no. 9, pp. 1166–1169, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. H.-S. Lee, S.-H. Jung, B.-S. Yun, and K.-W. Lee, “Isolation of chebulic acid from Terminalia chebula Retz. and its antioxidant effect in isolated rat hepatocytes,” Archives of Toxicology, vol. 81, no. 3, pp. 211–218, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Yang, J. Xiu, J. Liu et al., “Chebulagic acid, a hydrolyzable tannin, exhibited antiviral activity in vitro and in vivo against human enterovirus 71,” International Journal of Molecular Sciences, vol. 14, no. 5, pp. 9618–9627, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Banerjee, G. Mukherjee, and K. C. Patra, “Microbial transformation of tannin-rich substrate to gallic acid through co-culture method,” Bioresource Technology, vol. 96, no. 8, pp. 949–953, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. D. B. Reddy and P. Reddanna, “Chebulagic acid (CA) attenuates LPS-induced inflammation by suppressing NF-κB and MAPK activation in RAW 264.7 macrophages,” Biochemical and Biophysical Research Communications, vol. 381, no. 1, pp. 112–117, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. Y.-N. Huang, D.-D. Zhao, B. Gao et al., “Anti-hyperglycemic effect of chebulagic acid from the fruits of Terminalia chebula Retz,” International Journal of Molecular Sciences, vol. 13, no. 5, pp. 6320–6333, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. H. J. Kim, J. Kim, K. S. Kang, K. T. Lee, and H. O. Yang, “Neuroprotective effect of chebulagic acid via autophagy induction in SH-SY5Y cells,” Biomolecules and Therapeutics, vol. 22, no. 4, pp. 275–281, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. A. P. Athira, A. Helen, K. Saja, P. Reddanna, and P. R. Sudhakaran, “Inhibition of angiogenesis in vitro by chebulagic acid: a COX-LOX dual inhibitor,” International Journal of Vascular Medicine, vol. 2013, Article ID 843897, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Kumar, D. Gangappa, G. Gupta, and R. Karnati, “Chebulagic acid from Terminalia chebula causes G1 arrest, inhibits NFκB and induces apoptosis in retinoblastoma cells,” BMC Complementary and Alternative Medicine, vol. 14, article 319, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. V. Mishra, M. Agrawal, S. A. Onasanwo et al., “Anti-secretory and cyto-protective effects of chebulinic acid isolated from the fruits of Terminalia chebula on gastric ulcers,” Phytomedicine, vol. 20, no. 6, pp. 506–511, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. K. Lu, D. Chakroborty, C. Sarkar et al., “Triphala and its active constituent chebulinic acid are natural inhibitors of vascular endothelial growth factor-a mediated angiogenesis,” PLoS ONE, vol. 7, no. 8, Article ID e43934, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. Z.-C. Yi, Z. Wang, H.-X. Li, M.-J. Liu, R.-C. Wu, and X.-H. Wang, “Effects of chebulinic acid on differentiation of human leukemia K562 cells,” Acta Pharmacologica Sinica, vol. 25, no. 2, pp. 231–238, 2004. View at Google Scholar · View at Scopus
  52. T. Tanaka, I. Kouno, and G.-I. Nonaka, “Glutathione-mediated conversion of the ellagitannin geraniin into chebulagic acid,” Chemical and Pharmaceutical Bulletin, vol. 44, no. 1, pp. 34–40, 1996. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Mansouri, A. Hemmati, B. Naghizadeh, S. Mard, A. Rezaie, and B. Ghorbanzadeh, “A study of the mechanisms underlying the anti-inflammatory effect of ellagic acid in carrageenan-induced paw edema in rats,” Indian Journal of Pharmacology, vol. 47, no. 3, pp. 292–298, 2015. View at Publisher · View at Google Scholar
  54. S. Goswami, M. Vishwanath, S. Gangadarappa, R. Razdan, and M. Inamdar, “Efficacy of ellagic acid and sildenafil in diabetes-induced sexual dysfunction,” Pharmacognosy Magazine, vol. 10, supplement 3, pp. 581–587, 2014. View at Google Scholar
  55. W. R. García-Niño and C. Zazueta, “Ellagic acid: pharmacological activities and molecular mechanisms involved in liver protection,” Pharmacological Research, vol. 97, pp. 84–103, 2015. View at Publisher · View at Google Scholar
  56. M. Dianat, N. Amini, M. Badavi, and Y. Farbood, “Ellagic acid improved arrhythmias induced by CaCL2 in the rat stress model,” Avicenna Journal of Phytomedicine, vol. 5, no. 2, pp. 120–127, 2015. View at Google Scholar
  57. M. Dolatshahi, Y. Farbood, A. Sarkaki, S. M. T. Mansouri, and A. Khodadadi, “Ellagic acid improves hyperalgesia and cognitive deficiency in 6-hydroxidopamine induced rat model of Parkinson’s disease,” Iranian Journal of Basic Medical Sciences, vol. 18, no. 1, pp. 38–46, 2015. View at Google Scholar · View at Scopus
  58. Y. Farbood, A. Sarkaki, M. Dianat, A. Khodadadi, M. K. Haddad, and S. Mashhadizadeh, “Ellagic acid prevents cognitive and hippocampal long-term potentiation deficits and brain inflammation in rat with traumatic brain injury,” Life Sciences, vol. 124, pp. 120–127, 2015. View at Publisher · View at Google Scholar
  59. C. Wang, D. Zhang, H. Ma, and J. Liu, “Neuroprotective effects of emodin-8-O-β-d-glucoside in vivo and in vitro,” European Journal of Pharmacology, vol. 577, no. 1–3, pp. 58–63, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. Y.-L. Xu, L.-Y. Tang, X.-D. Zhou, G.-H. Zhou, and Z.-J. Wang, “Five new anthraquinones from the seed of Cassia obtusifolia,” Archives of Pharmacal Research, vol. 38, no. 6, pp. 1054–1058, 2015. View at Publisher · View at Google Scholar · View at Scopus
  61. P. C. Gupta, “Biological and pharmacological properties of Terminalia chebula retz. (haritaki)- an overview,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 4, supplement 3, pp. 62–68, 2012. View at Google Scholar · View at Scopus
  62. A. Bag, S. K. Bhattacharyya, and R. R. Chattopadhyay, “The development of Terminalia chebula Retz. (Combretaceae) in clinical research,” Asian Pacific Journal of Tropical Biomedicine, vol. 3, no. 3, pp. 244–252, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. I. Mueller-Harvey, “Analysis of hydrolysable tannins,” Animal Feed Science and Technology, vol. 91, no. 1-2, pp. 3–20, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. N. Lokeswari and K. J. Raju, “Optimization of gallic acid production from terminalia chebula by Aspergillus niger,” E-Journal of Chemistry, vol. 4, no. 2, pp. 287–293, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. R. Niemetz and G. G. Gross, “Enzymology of gallotannin and ellagitannin biosynthesis,” Phytochemistry, vol. 66, no. 17, pp. 2001–2011, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. T. Yoshida, Y. Amakura, and M. Yoshimura, “Structural features and biological properties of ellagitannins in some plant families of the order myrtales,” International Journal of Molecular Sciences, vol. 11, no. 1, pp. 79–106, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. P.-S. Chen and J.-H. Li, “Chemopreventive effect of punicalagin, a novel tannin component isolated from Terminalia catappa, on H-ras-transformed NIH3T3 cells,” Toxicology Letters, vol. 163, no. 1, pp. 44–53, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. Q. Han, J. Song, C. Qiao, L. Wong, and H. Xu, “Preparative isolation of hydrolysable tannins chebulagic acid and chebulinic acid from Terminalia chebula by high-speed counter-current chromatography,” Journal of Separation Science, vol. 29, no. 11, pp. 1653–1657, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. H. K. Sharma, S. Soni, P. Kaushal, and C. Singh, “Effect of process parameters on the antioxidant activities of bioactive compounds from Harad (Terminalia chebula retz.) Shilpa Soni, H.K. Sharma, Pragati Kaushal and C. Singh Food Engineering & Technology Department, Sant Longowal Institute of Engineeri,” Agricultural Engineering International: CIGR Journal, vol. 17, no. 2, 2015. View at Google Scholar
  70. G. K. B. Lopes, H. M. Schulman, and M. Hermes-Lima, “Polyphenol tannic acid inhibits hydroxyl radical formation from Fenton reaction by complexing ferrous ions,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1472, no. 1-2, pp. 142–152, 1999. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Surveswaran, Y.-Z. Cai, H. Corke, and M. Sun, “Systematic evaluation of natural phenolic antioxidants from 133 Indian medicinal plants,” Food Chemistry, vol. 102, no. 3, pp. 938–953, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. P. Onial, R. Dayal, M. Rawat, and R. Kumar, “Utilization of Terminalia chebula Retz. fruits pericarp as a source of natural dye for textile applications,” Indian Journal of Natural Products and Resources (IJNPR), vol. 6, no. 2, pp. 114–121, 2015. View at Google Scholar
  73. H. G. Kim, J. H. Cho, E. Y. Jeong, J. H. Lim, S. H. Lee, and H. S. Lee, “Growth-inhibiting activity of active component isolated from Terminalia chebula fruits against intestinal bacteria,” Journal of Food Protection, vol. 69, no. 9, pp. 2205–2209, 2006. View at Google Scholar · View at Scopus
  74. P. Onial, M. Rawat, and R. Dayal, “Chemical studies of fatty oil of Terminalia chebula seeds kernels,” Analytical Chemistry Letters, vol. 4, no. 5-6, pp. 359–363, 2014. View at Publisher · View at Google Scholar
  75. X. Zhang, C. Chen, S. He, and F. Ge, “Supercritical-CO2 fluid extraction of the fatty oil in Terminalia chebula and GC-MS analysis,” Journal of Chinese Medicinal Materials, vol. 20, no. 9, pp. 463–464, 1997. View at Google Scholar · View at Scopus
  76. D. B. Reddy, T. C. M. Reddy, G. Jyotsna et al., “Chebulagic acid, a COX–LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz., induces apoptosis in COLO-205 cell line,” Journal of Ethnopharmacology, vol. 124, no. 3, pp. 506–512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. P. Anand, B. Singh, and N. Singh, “A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease,” Bioorganic and Medicinal Chemistry, vol. 20, no. 3, pp. 1175–1180, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Pohanka, “Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology,” International Journal of Molecular Sciences, vol. 13, no. 2, pp. 2219–2238, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. J. R. Suarez-Lopez, J. H. Himes, D. R. Jacobs Jr., B. H. Alexander, and M. R. Gunnar, “Acetylcholinesterase activity and neurodevelopment in boys and girls,” Pediatrics, vol. 132, no. 6, pp. e1649–e1658, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. C. F. Bartels, T. Zelinski, and O. Lockridge, “Mutation at codon 322 in the human acetylcholinesterase (ACHE) gene accounts for YT blood group polymorphism,” The American Journal of Human Genetics, vol. 52, no. 5, pp. 928–936, 1993. View at Google Scholar · View at Scopus
  81. S. Greenfield and D. J. Vaux, “Parkinson's disease, Alzheimer's disease and motor neurone disease: identifying a common mechanism,” Neuroscience, vol. 113, no. 3, pp. 485–492, 2002. View at Publisher · View at Google Scholar · View at Scopus
  82. T. Day and S. A. Greenfield, “A peptide derived from acetylcholinesterase induces neuronal cell death: characterisation of possible mechanisms,” Experimental Brain Research, vol. 153, no. 3, pp. 334–342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  83. P. T. Francis, A. Nordberg, and S. E. Arnold, “A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?” Trends in Pharmacological Sciences, vol. 26, no. 2, pp. 104–111, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. T. Darreh-Shori, E. Hellström-Lindahl, C. Flores-Flores, Z. Z. Guan, H. Soreq, and A. Nordberg, “Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients,” Journal of Neurochemistry, vol. 88, no. 5, pp. 1102–1113, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Borisovskaya, M. Pascualy, and S. Borson, “Cognitive and neuropsychiatric impairments in Alzheimer's disease: current treatment strategies,” Current Psychiatry Reports, vol. 16, no. 9, pp. 1–9, 2014. View at Publisher · View at Google Scholar
  86. M. H. Oh, P. J. Houghton, W. K. Whang, and J. H. Cho, “Screening of Korean herbal medicines used to improve cognitive function for anti-cholinesterase activity,” Phytomedicine, vol. 11, no. 6, pp. 544–548, 2004. View at Publisher · View at Google Scholar · View at Scopus
  87. V. Schulz, “Ginkgo extract or cholinesterase inhibitors in patients with dementia: what clinical trials and guidelines fail to consider,” Phytomedicine, vol. 10, no. 4, pp. 74–79, 2003. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Sancheti, S. Sancheti, B.-H. Um, and S.-Y. Seo, “1,2,3,4,6-penta-O-galloyl-β-D-glucose: a cholinesterase inhibitor from Terminalia chebula,” South African Journal of Botany, vol. 76, no. 2, pp. 285–288, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. G. Nag and B. De, “Acetylcholinesterase inhibitory activity of Terminalia chebula, Terminalia bellerica and Emblica officinalis and some phenolic compounds,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 3, no. 3, pp. 121–124, 2011. View at Google Scholar · View at Scopus
  90. A. P. Murray, M. B. Faraoni, M. J. Castro, N. P. Alza, and V. Cavallaro, “Natural AChE inhibitors from plants and their contribution to Alzheimer’s disease therapy,” Current Neuropharmacology, vol. 11, no. 4, pp. 388–413, 2013. View at Publisher · View at Google Scholar
  91. C. Sulaiman, C. Sadashiva, S. George, and I. Balachandran, “Acetylcholinestrase inhibition and antioxidant activity of Terminalia chebula, Retz,” Journal of Tropical Medicinal Plants, vol. 13, no. 2, pp. 125–127, 2012. View at Google Scholar
  92. A. Upadhyay and D. K. Singh, “Inhibition kinetics of certain enzymes in the nervous tissue of vector snail Lymnaea acuminata by active molluscicidal components of Sapindus mukorossi and Terminalia chebula,” Chemosphere, vol. 85, no. 6, pp. 1095–1100, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Parle and M. Vasudevan, “Memory enhancing activity of Abana: an indian ayurvedic poly-herbal formulation,” Journal of Health Science, vol. 53, no. 1, pp. 43–52, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. H. Walia, J. Kaur, and S. Arora, “Antioxidant efficacy of fruit extracts of Terminalia chebula prepared by sequential method using TA-102 strain of Salmonella typhimurium,” Spatula DD, vol. 2, no. 2, pp. 165–171, 2012. View at Publisher · View at Google Scholar
  95. P. Dhivya, M. Sobiya, P. Selvamani, and S. Latha, “An approach to Alzheimer's disease treatment with cholinesterase inhibitory activity from various plant species,” International Journal of PharmTech Research, vol. 6, no. 5, pp. 1450–1467, 2014. View at Google Scholar
  96. P. Pithayanukul, P. Ruenraroengsak, R. Bavovada, N. Pakmanee, and R. Suttisri, “In vitro. Investigation of the protective effects of tannic acid against the activities of Naja kaouthia. Venom,” Pharmaceutical Biology, vol. 45, no. 2, pp. 94–97, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Mathew and S. Subramanian, “In vitro screening for anti-cholinesterase and antioxidant activity of methanolic extracts of ayurvedic medicinal plants used for cognitive disorders,” PLoS ONE, vol. 9, no. 1, Article ID e86804, 2014. View at Publisher · View at Google Scholar · View at Scopus
  98. T. Y. Shin, H. J. Jeong, D. K. Kim et al., “Inhibitory action of water soluble fraction of Terminalia chebula on systemic and local anaphylaxis,” Journal of Ethnopharmacology, vol. 74, no. 2, pp. 133–140, 2001. View at Publisher · View at Google Scholar · View at Scopus
  99. K.-C. Choi, Y.-H. Lee, M. G. Jung et al., “Gallic acid suppresses lipopolysaccharide-induced nuclear factor-κB signaling by preventing RelA acetylation in A549 lung cancer cells,” Molecular Cancer Research, vol. 7, no. 12, pp. 2011–2021, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. N. D. Das, K. H. Jung, J. H. Park et al., “Terminalia chebula extract acts as a potential NF-κB inhibitor in human lymphoblastic T cells,” Phytotherapy Research, vol. 25, no. 6, pp. 927–934, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. M.-J. Kim, A.-R. Seong, J.-Y. Yoo et al., “Gallic acid, a histone acetyltransferase inhibitor, suppresses β-amyloid neurotoxicity by inhibiting microglial-mediated neuroinflammation,” Molecular Nutrition & Food Research, vol. 55, no. 12, pp. 1798–1808, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. Y.-J. Wang, P. Thomas, J.-H. Zhong et al., “Consumption of grape seed extract prevents amyloid-β deposition and attenuates inflammation in brain of an alzheimer's disease mouse,” Neurotoxicity Research, vol. 15, no. 1, pp. 3–14, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. S.-H. Kim, C.-D. Jun, K. Suk et al., “Gallic acid inhibits histamine release and pro-inflammatory cytokine production in mast cells,” Toxicological Sciences, vol. 91, no. 1, pp. 123–131, 2006. View at Publisher · View at Google Scholar · View at Scopus
  104. V. Nair, S. Singh, and Y. K. Gupta, “Anti-arthritic and disease modifying activity of Terminalia chebula Retz. in experimental models,” Journal of Pharmacy and Pharmacology, vol. 62, no. 12, pp. 1801–1806, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. T. Moeslinger, R. Friedl, I. Volf, M. Brunner, E. Koller, and P. G. Spieckermann, “Inhibition of inducible nitric oxide synthesis by the herbal preparation Padma 28 in macrophage cell line,” Canadian Journal of Physiology and Pharmacology, vol. 78, no. 11, pp. 861–866, 2000. View at Publisher · View at Google Scholar · View at Scopus
  106. R. Patil, B. Nanjwade, and F. Manvi, “Evaluation of anti-inflammatory and antiarthritic effect of sesbania grandiflora bark and fruit of Terminalia chebula in rats,” International Journal of Pharmacology and Biological Sciences, vol. 5, no. 1, pp. 37–46, 2011. View at Google Scholar
  107. A. Bag, S. Kumar Bhattacharyya, N. Kumar Pal, and R. R. Chattopadhyay, “Anti-inflammatory, anti-lipid peroxidative, antioxidant and membrane stabilizing activities of hydroalcoholic extract of Terminalia chebula fruits,” Pharmaceutical Biology, vol. 51, no. 12, pp. 1515–1520, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. E. P. Sabina and M. Rasool, “An in vivo and in vitro potential of Indian ayurvedic herbal formulation Triphala on experimental gouty arthritis in mice,” Vascular Pharmacology, vol. 48, no. 1, pp. 14–20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. Y. R. Ramani and S. Pradhan, “Antiarthritic activity of acetone extract of Terminalia chebula,” WebmedCentral Pharmacology, vol. 3, no. 2, Article ID WMC003057, pp. 1–9, 2012. View at Publisher · View at Google Scholar
  110. P. Srivastava, H. N. Raut, R. S. Wagh, H. M. Puntambekar, and M. J. Kulkarni, “Purification and characterization of an antioxidant protein (~16 kDa) from Terminalia chebula fruit,” Food Chemistry, vol. 131, no. 1, pp. 141–148, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. C. S. Atwood, M. E. Obrenovich, T. Liu et al., “Amyloid-β: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-β,” Brain Research Reviews, vol. 43, no. 1, pp. 1–16, 2003. View at Publisher · View at Google Scholar · View at Scopus
  112. B. Uttara, A. V. Singh, P. Zamboni, and R. T. Mahajan, “Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options,” Current Neuropharmacology, vol. 7, no. 1, pp. 65–74, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. K. Hensley, N. Hall, R. Subramaniam et al., “Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation,” Journal of Neurochemistry, vol. 65, no. 5, pp. 2146–2156, 1995. View at Google Scholar · View at Scopus
  114. K. Hensley, J. Carney, N. Hall, W. Shaw, and D. A. Butterfield, “Electron paramagnetic resonance investigations of free radical-induced alterations in neocortical synaptosomal membrane protein infrastructure,” Free Radical Biology and Medicine, vol. 17, no. 4, pp. 321–331, 1994. View at Publisher · View at Google Scholar · View at Scopus
  115. R. X. Santos, S. C. Correia, X. Zhu et al., “Mitochondrial DNA oxidative damage and repair in aging and Alzheimer's disease,” Antioxidants & Redox Signaling, vol. 18, no. 18, pp. 2444–2457, 2013. View at Publisher · View at Google Scholar · View at Scopus
  116. P. Mecocci, U. MacGarvey, and M. F. Beal, “Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease,” Annals of Neurology, vol. 36, no. 5, pp. 747–751, 1994. View at Publisher · View at Google Scholar · View at Scopus
  117. H.-T. Lee, C.-S. Lin, C.-S. Lee, C.-Y. Tsai, and Y.-H. Wei, “Increased 8-hydroxy-2′-deoxyguanosine in plasma and decreased mRNA expression of human 8-oxoguanine DNA glycosylase 1, anti-oxidant enzymes, mitochondrial biogenesis-related proteins and glycolytic enzymes in leucocytes in patients with systemic lupus erythematosus,” Clinical & Experimental Immunology, vol. 176, no. 1, pp. 66–77, 2014. View at Publisher · View at Google Scholar · View at Scopus
  118. M. A. Lovell, W. D. Ehmann, S. M. Butler, and W. R. Markesbery, “Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease,” Neurology, vol. 45, no. 8, pp. 1594–1601, 1995. View at Publisher · View at Google Scholar · View at Scopus
  119. K. V. Subbarao, J. S. Richardson, and L. C. Ang, “Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro,” Journal of Neurochemistry, vol. 55, no. 1, pp. 342–345, 1990. View at Publisher · View at Google Scholar · View at Scopus
  120. I. T. Lott, “Antioxidants in Down syndrome,” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1822, no. 5, pp. 657–663, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. L. Whiley, A. Sen, J. Heaton et al., “Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease,” Neurobiology of Aging, vol. 35, no. 2, pp. 271–278, 2014. View at Publisher · View at Google Scholar · View at Scopus
  122. R. J. Mark, M. A. Lovell, W. R. Markesbery, K. Uchida, and M. P. Mattson, “A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid β-peptide,” Journal of Neurochemistry, vol. 68, no. 1, pp. 255–264, 1997. View at Google Scholar · View at Scopus
  123. A. Klugman, D. P. Naughton, M. Isaac, I. Shah, A. Petroczi, and N. Tabet, “Antioxidant enzymatic activities in alzheimer's disease: the relationship to acetylcholinesterase inhibitors,” Journal of Alzheimer's Disease, vol. 30, no. 3, pp. 467–474, 2012. View at Publisher · View at Google Scholar · View at Scopus
  124. L. Balazs and M. Leon, “Evidence of an oxidative challenge in the Alzheimer's brain,” Neurochemical Research, vol. 19, no. 9, pp. 1131–1137, 1994. View at Publisher · View at Google Scholar · View at Scopus
  125. R. A. Omar, Y.-J. Chyan, A. C. Andorn, B. Poeggeler, N. K. Robakis, and M. A. Pappolla, “Increased expression but reduced activity of antioxidant enzymes in Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 1, no. 3, pp. 139–145, 1999. View at Google Scholar · View at Scopus
  126. N. Sasaki, S. Toki, H. Chowei et al., “Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease,” Brain Research, vol. 888, no. 2, pp. 256–262, 2001. View at Publisher · View at Google Scholar · View at Scopus
  127. N. Verma and M. Vinayak, “Effect of Terminalia arjuna on antioxidant defense system in cancer,” Molecular Biology Reports, vol. 36, no. 1, pp. 159–164, 2009. View at Publisher · View at Google Scholar · View at Scopus
  128. A. Khan, H. Nazar, S. M. Sabir et al., “Antioxidant activity and inhibitory effect of some commonly used medicinal plants against lipid per-oxidation in mice brain,” African Journal of Traditional, Complementary and Alternative Medicines, vol. 11, no. 5, pp. 83–90, 2014. View at Publisher · View at Google Scholar · View at Scopus
  129. M. K. Gautam, S. Goel, R. R. Ghatule, A. Singh, G. Nath, and R. K. Goel, “Curative effect of Terminalia chebula extract on acetic acid-induced experimental colitis: role of antioxidants, free radicals and acute inflammatory marker,” Inflammopharmacology, vol. 21, no. 5, pp. 377–383, 2013. View at Publisher · View at Google Scholar · View at Scopus
  130. C. L. Chang and C. S. Lin, “Phytochemical composition, antioxidant activity, and neuroprotective effect of Terminalia chebula Retzius extracts,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 125247, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  131. J. H. Park, H. S. Joo, K.-Y. Yoo et al., “Extract from Terminalia chebula seeds protect against experimental ischemic neuronal damage via maintaining SODs and BDNF levels,” Neurochemical Research, vol. 36, no. 11, pp. 2043–2050, 2011. View at Publisher · View at Google Scholar · View at Scopus
  132. M. Na, K. Bae, S. Sik Kang et al., “Cytoprotective effect on oxidative stress and inhibitory effect on cellular aging of Terminalia chebula fruit,” Phytotherapy Research, vol. 18, no. 9, pp. 737–741, 2004. View at Publisher · View at Google Scholar · View at Scopus
  133. R. Mahesh, S. Bhuvana, and V. M. H. Begum, “Effect of Terminalia chebula aqueous extract on oxidative stress and antioxidant status in the liver and kidney of young and aged rats,” Cell Biochemistry and Function, vol. 27, no. 6, pp. 358–363, 2009. View at Publisher · View at Google Scholar · View at Scopus
  134. H.-Y. Cheng, T.-C. Lin, K.-H. Yu, C.-M. Yang, and C.-C. Lin, “Antioxidant and free radical scavenging activities of Terminalia chebula,” Biological and Pharmaceutical Bulletin, vol. 26, no. 9, pp. 1331–1335, 2003. View at Publisher · View at Google Scholar · View at Scopus
  135. R. Sarkar and N. Mandal, “Hydroalcoholic extracts of Indian medicinal plants can help in amelioration from oxidative stress through antioxidant properties,” Journal of Complementary and Integrative Medicine, vol. 9, no. 1, pp. 1–9, 2012. View at Google Scholar · View at Scopus
  136. A. Manosroi, P. Jantrawut, T. Akihisa, W. Manosroi, and J. Manosroi, “In vitro anti-aging activities of Terminalia chebula gall extract,” Pharmaceutical Biology, vol. 48, no. 4, pp. 469–481, 2010. View at Publisher · View at Google Scholar · View at Scopus
  137. K. W. Lee, Y. J. Kim, D.-O. Kim, H. J. Lee, and C. Y. Lee, “Major phenolics in apple and their contribution to the total antioxidant capacity,” Journal of Agricultural and Food Chemistry, vol. 51, no. 22, pp. 6516–6520, 2003. View at Publisher · View at Google Scholar · View at Scopus
  138. S. C. Mondal, P. Singh, B. Kumar, S. K. Singh, S. K. Gupta, and A. Verma, “Ageing and potential anti-aging phytochemicals: an overview,” World Journal of Pharmacy and Pharmaceutical Sciences, vol. 4, no. 1, pp. 426–454, 2014. View at Google Scholar